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ORIGINAL INVESTIGATION
The Causes, Treatment, and Outcome of Acute
Heart Failure in 1006 Africans From 9 Countries
Results of the Sub-Saharan Africa Survey of Heart Failure
Albertino Damasceno, MD, PhD; Bongani M. Mayosi, DPhil, FCP(SA); Mahmoud Sani, MBBS;
Okechukwu S. Ogah, MBBS; Charles Mondo, MBChB, PhD; Dike Ojji, MBBS; Anastase Dzudie, MD;
Charles Kouam Kouam, MD; Ahmed Suliman, MD; Neshaad Schrueder, MBChB, FCP(SA);
Gerald Yonga, MBChB; Serigne Abdou Ba, MD; Fikru Maru, MD; Bekele Alemayehu, MD;
Christopher Edwards, BS; Beth A. Davison, PhD; Gad Cotter, MD; Karen Sliwa, MD, PhD
Background: Acute heart failure (AHF) in sub-Saharan
Africahasnotbeenwell characterized.Therefore,we sought
to describe the characteristics, treatment, and outcomes of
patients admitted with AHF in sub-Saharan Africa.
Methods: The Sub-Saharan Africa Survey of Heart
Failure (THESUS–HF) was a prospective, multicenter,
observational survey of patients with AHF admitted to
12 university hospitals in 9 countries. Among patients
presenting with AHF, we determined the causes, treat-
ment, and outcomes during 6 months of follow-up.
Results: From July 1, 2007, to June 30, 2010, we en-
rolled 1006 patients presentingwith AHF.Mean (SD) age
was 52.3 (18.3) years, 511 (50.8%) were women, and the
predominant racewas blackAfrican (984 of 999 [98.5%]).
Mean (SD) left ventricular ejection fraction was 39.5%
(16.5%). Heart failure wasmost commonly due to hyper-
tension (n=453 [45.4%]) and rheumatic heart disease
(n=143 [14.3%]). Ischemic heart disease (n=77 [7.7%])
was not a common cause of AHF. Concurrent renal dys-
function (estimated glomerular filtration rate, 30 mL/
min/173m2), diabetesmellitus, anemia (hemoglobin level,
10 g/dL), and atrial fibrillationwere found in 73 (7.7%),
114 (11.4%), 147 (15.2%), and 184 cases (18.3%), respec-
tively; 65 of 500 patients undergoing testing (13.0%)were
seropositive for the human immunodeficiency virus. The
medianhospital staywas 7days (interquartile range, 5-10),
with an in-hospital mortality of 4.2%. Estimated 180-day
mortality was 17.8% (95% CI, 15.4%-20.6%). Most pa-
tients were treated with renin-angiotensin system block-
ers but not -blockers at discharge. Hydralazine hydro-
chloride and nitrates were rarely used.
Conclusions: In African patients, AHF has a predomi-
nantly nonischemic cause, most commonly hyperten-
sion. The condition occurs inmiddle-aged adults, equally
in men and women, and is associated with high mortal-
ity. The outcome is similar to that observed in non-
African AHF registries, suggesting that AHF has a dire
prognosis globally, regardless of the cause.
Arch Intern Med. 2012;172(18):1386-1394.
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H EART FAILURE (HF) ANDespecia l ly acute HF(AHF) are importantcauses of morbidity andmortality in the devel-
oped world. The high rate of rehospital-
ization, the unproductive years of life,
and the price of treatment constitute an
important economic burden. Little is
known about acute and chronic HF in
sub-Saharan Africa.1 Recent studies2-5
suggested that the main underlying
causes of HF are different in Africa,
including some conditions that are
almost unique, such as endomyocardial
fibrosis and tuberculous pericarditis,6,7 as
well as a high prevalence of peripartum
cardiomyopathy and idiopathic dilated
cardiomyopathy.8 At the same time, with
a nonuniform epidemiologic transition to
a more Western way of living, preva-
lences of hypertension, obesity, and dia-
betes are increasing, particularly in urban
centers, with a possible effect on the eti-
ology of HF.9
The Sub-Saharan Africa Survey of
Heart Failure (THESUS–HF) was initi-
ated to determine the causes and treat-
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ment of AHF and morbidity and mortality among
those with the disease in the African subcontinent.
METHODS
STUDY DESIGN AND CLINICAL SETTING
We conducted THESUS–HF as a prospective, multicenter, in-
ternational observational survey in 12 cardiology centers from
9 countries in the southern, eastern, central, and western re-
gions of sub-Saharan Africa. The countries and centers were
selected on the basis of availability of a physician trained in clini-
cal cardiology and echocardiography who had previously par-
ticipated in research projects. Ethiopia, Kenya, and Senegal
joined the study late, resulting in a shorter enrollment period.
INCLUSION AND EXCLUSION CRITERIA
Patients older than 12 years admitted with dyspnea as themain
complaint and diagnosed with AHF based on symptoms and
signs that were confirmed by echocardiography (de novo or de-
compensation of previously diagnosedHF)were enrolled in the
present study. Exclusion criteria were acute ST-elevationmyo-
cardial infarction, severe known renal failure (patients under-
going dialysis or with a creatinine level of4 mg/dL) (to con-
vert to micromoles per liter, multiply by 88.4), nephrotic
syndrome, hepatic failure, or another cause of hypoalbumin-
emia. Written informed consent was obtained from each sub-
ject who was enrolled into the study. Ethical approval was ob-
tained from the ethical review board of the participating
institutions, and the study conformed to the principles out-
lined in the Declaration of Helsinki.
DATA COLLECTION AND CASE DEFINITION
A comprehensive range of clinical data was collected on a stan-
dardized case report form. A detailed echocardiographic as-
sessment of ventricular function, valvular structure and func-
tion, and regional wall abnormalities was performed. All
echocardiographic procedures were undertaken by trained phy-
sicians, andmeasurements were made according to the Ameri-
can Society of Echocardiography Guidelines.10 Electrocardio-
grams were read centrally by a cardiologist at Momentum
Research, Inc, using standard reference ranges.11 Laboratory
evaluations provided by the local institution and intravenous
and oral medications were recorded at admission and on days
1, 2, and 7 (or at discharge if earlier). Symptoms and signs of
HF, vital signs, and laboratory test data (when indicated) were
collected at baseline and through day 7 (or at discharge if ear-
lier). The probable primary cause of HF was based on the Eu-
ropean Society of Cardiology guidelines12 and as recently ap-
plied in the chronic HF cohort of the Heart of Soweto Study.13
Ischemic causes were determined on the basis of accepted cri-
teria, such as history, or results of noninvasive (eg, electrocar-
diography, stress test) or invasive tests when available. Test-
ing for human immunodeficiency virus infection was only
performedwhen clinical findings raised suspicion and after pa-
tient consent was obtained.
Subjects underwent evaluation for symptoms and signs ofHF
and laboratory testing (when indicated) at the 1- and 6-month
follow-ups. Information on readmissions and death,with respec-
tive reasons and cause,was collected through the6-month follow-
up. We initiated telephone contact with patients who could not
attend additional clinic visits because they moved to a different
location or to another province. Patients who could not be con-
tacted were censored at the last available contact.
To better understand the changes in the pattern of AHF in
Africa, the present cohort was classified as having endemic
causes (group 1; ie, rheumatic heart disease, the cardiomy-
opathies, and infective causes, such as pericarditis and human
immunodeficiency virus–associated cardiomyopathy), and
emerging causes (group 2; ie, hypertension and ischemic
heart disease).14-17
STATISTICAL ANALYSES
All data were processed atMomentumResearch, Inc. Data were
verified and analyzed using commercially available software
(SAS, version 9.2; SAS Institute, Inc). Continuous data were
presented asmean (SD) ormedian (interquartile range, ie, 25th
and 75th percentiles). Continuous variables were compared
using 2-tailed, 2-sample t tests and categorical variables using
2 tests. Sex-adjusted differences between patients with emerg-
ing and endemic causes were estimated using weighted least
squares regression for dichotomous characteristics and ordi-
nary linear regression for continuous characteristics. Kaplan-
Meier estimates of mortality and readmission rates were pro-
vided. The time to the first event was considered; times for
patients without the event of interest were censored at the ear-
lier of the last date the patient was known to be alive or the
period of interest.
RESULTS
BASELINE PATIENT CHARACTERISTICS
ON ADMISSION
From July 1, 2007, to June 30, 2010, 1011 patients were
enrolled in the study, for whom 1006 case report forms
were received (Figure 1).
Table 1 shows the demographic and clinical presen-
tation on admission for the entire cohort and compares
men with women (50.8% of the cohort). Electrocardio-
graphic strips were available for 814 patients. The most
frequent arrhythmia was atrial fibrillation, which was
found in 147 of 806 patients (18.2%). The most frequent
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Figure 1. Patients included in the Sub-Saharan Africa Survey of Heart Failure
per country. Case report forms were available for 1006 of 1011 patients.
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conduction abnormality was left anterior hemiblock,
present in 143 of 804 patients (17.8%). Complete left
and right bundle branch blocks were seen in 62 of 803
(7.7%) and 39 of 803 patients (4.9%), respectively.
CAUSES OF HF
Figure 2 shows the causes of HF in the entire study co-
hort. In some patients, more than 1 cause was identified.
Table 2 shows the characteristics by endemic vs emerg-
ing HF causes and interaction of those causes with sex.
Figure 3 shows the different causes of AHF by country.
THERAPIES FOR HF
The most commonly administered intravenous medi-
cation at admission was furosemide in 927 of 998
patients (92.9%), with use decreasing to only 215 of
938 patients (22.9%) at day 7 or discharge. The next
commonly administered parenteral drugs on admis-
sion were digoxin in 13.7% and nitrates in 7.9%.
Parenteral inotropes (ie, dopamine hydrochloride and
dobutamine hydrochloride) were used in 5.0% and
5.1%, respectively, on admission. Mechanical
ventilation was rarely used (0.6%). Figure 4 shows
Table 1. Demographic and Clinical Presentationa
Characteristic
All
(N=1006)
Men
(n=494)
Women
(n=511) P Value
Age, y
Mean (SD) 52.3 (18.3) 54.0 (16.9) 50.7 (19.5) .005
Median (IQR) 55.0 (39.0-67.0) 55.0 (43.0-67.0) 53.0 (33.0-67.0)
Black African, No. (%) 984 (98.5) 486 (98.8) 497 (98.2) .47
Atrial fibrillation, No. (%) 184 (18.3) 77 (15.7) 107 (21.1) .03
No. of AHF admissions in last 12 mo
Mean (SD) 0.37 (0.78) 0.41 (0.77) 0.34 (0.78) .15Median (IQR) 0 (0-0) 0 (0-1) 0 (0-0)
Hyperlipidemia, No. (%)b 90 (9.2) 52 (10.8) 38 (7.6) .09
History of smoking, No. (%) 98 (9.8) 85 (17.3) 13 (2.6) .001
History of hypertension, No. (%) 556 (55.5) 296 (60.0) 259 (51.0) .004
History of diabetes mellitus, No. (%) 114 (11.4) 58 (11.8) 56 (11.0) .68
Body mass indexc
Mean (SD) 25.2 (9.0) 24.7 (4.9) 25.7 (11.6) .08Median (IQR) 24.0 (20.9-28.1) 24.0 (21.2-27.6) 23.9 (20.5-28.6)
Systolic blood pressure, mm Hg
Mean (SD) 130.4 (33.5) 132.4 (33.7) 128.4 (33.3) .06Median (IQR) 126.5 (106.0-150.0) 130.0 (110.0-151.0) 120.0 (102.0-150.0)
Diastolic blood pressure, mm Hg
Mean (SD) 84.3 (20.9) 85.5 (21.2) 83.2 (20.7) .08Median (IQR) 80.0 (70.0-100.0) 82.0 (70.0-100.0) 80.0 (70.0-96.0)
Heart rate, bpm
Mean (SD) 103.7 (21.6) 101.6 (21.4) 105.7 (21.6) .003Median (IQR) 104.0 (90.0-116.0) 100.0 (88.0-112.0) 108.0 (90.0-120.0)
LVEF, %
Mean (SD) 39.5 (16.5) 37.8 (16.2) 41.1 (16.6) .002Median (IQR) 38.0 (27.0-50.0) 37.0 (25.0-112.0) 40.0 (28.4-53.0)
Creatinine level, mg/dL
Mean (SD) 1.44 (1.19) 1.57 (1.21) 1.30 (1.16)
.001Median (IQR) 1.12 (0.89-1.50) 1.23 (0.96-1.65) 1.01 (0.80-1.33)
SUN level, mg/dL
Mean (SD) 35.6 (34.1) 41.1 (38.9) 30.2 (27.7)
.001Median (IQR) 26.6 (16.5-42.0) 30.5 (20.0-49.0) 23.2 (14.3-34.5)
Sodium level, mEq/L
Mean (SD) 135.1 (6.6) 134.9 (6.5) 135.3 (6.8) .33Median (IQR) 135.8 (131.0-139.1) 135.0 (131.0-139.0) 146.0 (131.4-140.0)
Glucose level, mg/dL
Mean (SD) 109.7 (49.7) 109.7 (44.0) 109.5 (54.9) .94Median (IQR) 93.7 (84.0-117.0) 97.2 (84.6-122.0) 93.0 (82.8-111.6)
eGFR, mL/min/1.73 m2
Mean (SD) 83.3 (48.0) 85.3 (51.4) 81.4 (44.4) .20Median (IQR) 76.7 (54.0-103.5) 79.6 (55.5-106.2) 74.7 (52.6-101.3)
Renal dysfunction, No. (%)d 73 (7.7) 35 (7.5) 38 (7.8) .83
Hemoglobin level, g/dL
Mean (SD) 12.2 (2.6) 12.6 (2.6) 11.8 (2.5)
.001Median (IQR) 12.3 (10.7-13.7) 13.0 (11.0-14.5) 11.8 (10.5-13.1)
Anemia, No. (%)e 147 (15.2) 68 (14.3) 79 (16.1) .43
Total WBC count, No./µL
Mean (SD) 7699 (4092) 7484 (3505) 7914 (4581) .10Median (IQR) 6800 (5200-8980) 6700 (5200-8900) 6900 (5200-9000)
Lymphocyte count, %
Mean (SD) 30.3 (13.4) 29.8 (12.9) 30.9 (13.8) .25Median (IQR) 30.0 (20.0-39.6) 30.0 (20.0-39.0) 30.5 (20.3-40.0)
(continued)
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prescribed oral medications on admission and
follow-up.
PATIENTS’ FOLLOW-UP AND OUTCOMES
Of 1006 patients, 1-month follow-up assessments were
completed for 578 (57.5%) and 6-month assessments for
461 (45.8%). A total of 159 of 1006 patients (15.8%) died
without completing a 6-month assessment; an addi-
tional 316 (31.4%) had a last date known alive provided
and were included in the analysis. The remaining 70 pa-
tients (7.0%) were lost to follow-up. Reasons for loss to
follow-up were provided for 35 of these patients and in-
cluded lack of telephone contact (2.3%), financial con-
straints (0.3%), unwillingness to come for follow-up
(0.3%), lack of transportation to the site (0.1%), and
others, for example, transfer of care to other facilities
(0.5%). Table 3 reports the main clinical outcomes ob-
served in the study. The rate of death or readmission at
60 days was 15.4% (Figure 5A), and the estimated
6-month mortality rate was 17.8% (Figure 5B). Mortal-
ity rateswere similar among countries, except that a some-
what lower rate was reported in the Ugandan center
(6.3%).
COMMENT
To our knowledge, our data represent Africa’s first and
largest multinational prospective registry of AHF. This
registry reveals a few unique characteristics of AHF in
sub-Saharan Africa.
One of themost striking features of this cohort of Afri-
can patients with AHF is the relative youth of the pa-
tients affected (median age, 55 years). In industrialized
countries, AHF is a disease of the elderly, with a mean
age of 72 years (median age, 66-70 years)18; hence, the
condition presents 2 decades earlier in sub-SaharanAfrica.
Acute HF therefore strikes patients in the prime of their
lives in sub-Saharan Africa, with major economic impli-
cations because it affects the generation of bread-
winners and caregivers. With respect to sex, despite the
relative youth of the patients, the disease affects men and
women equally, although the characteristics and causes
Patients with acute heart failure1006
453 of 998 (45.4%) Hypertension
188 of 998 (18.8%) Idiopathic dilated cardiomyopathy
143 of 997 (14.3%) Rheumatic heart disease
77 of 999 (7.7%) Ischemic heart disease
77 of 1002 (7.7%) Peripartum cardiomyopathy
68 of 999 (6.8%) Pericardial effusion tamponade
39 of 986 (4.0%) Other endemic
34 of 986 (3.4%) Other emerging
26 of 1000 (2.6%) HIV cardiomyopathy
13 of 1000 (1.3%) Endomyocardial fibrosis
Figure 2. Causes of acute heart failure in the study cohort. Blue indicates
earlier stages of epidemiologic transition (endemic causes); pink, later stages
of epidemiologic transition (emerging causes); and HIV, human
immunodeficiency virus.
Table 1. Demographic and Clinical Presentationa (continued)
Characteristic
All
(N=1006)
Men
(n=494)
Women
(n=511) P Value
Cholesterol level, mg/dL
Mean (SD) 157.6 (54.2) 160.0 (59.0) 155.2 (49.1) .26Median (IQR) 152.1 (124.0-187.0) 156.0 (124.8-187.2) 152.1 (120.9-183.3)
Triglyceride level, mg/dL
Mean (SD) 106.2 (53.9) 109.8 (56.7) 102.7 (50.9) .09Median (IQR) 97.9 (71.2-124.6) 97.9 (73.5-125.0) 95.5 (71.2-124.6)
CK level, U/L
Mean (SD) 232.2 (447.7) 259.4 (412.6) 210.8 (473.9) .40Median (IQR) 88.0 (55.0-171.0) 110.0 (62.5-251.6) 83.0 (48.9-139.0)
CK-MB fraction, U/L
Mean (SD) 37.4 (76.0) 39.1 (83.9) 35.9 (68.6) .78Median (IQR) 19.0 (13.0-32.0) 19.0 (14.0-31.0) 20.0 (12.0-32.5)
Seropositive for HIV, No./No. undergoing
testing (%)
65/500 (13.0) 30/240 (12.5) 35/260 (13.5) .75f
Abbreviations: AHF, acute heart failure; CK, creatine kinase; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; IQR, interquartile
range; LVEF, left ventricular ejection fraction; SUN, serum urea nitrogen; WBC, white blood cell.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259; CK to microkatals per liter, multiply by 0.0167; creatinine to micromoles
per liter, multiply by 88.4; glucose to millimoles per liter, multiply by 0.0555; hemoglobin to grams per liter, multiply by 10.0; lymphocyte fraction to a proportion
of 1, multiply by 0.01; sodium to millimoles per liter, multiply by 1; SUN to millimoles per liter, multiply by 0.357; triglycerides to millimoles per liter, multiply
by 0.0113; WBC count to cells 109 per liter, multiply by 0.001.
aData are computed from nonmissing values, the number of which may vary from variable to variable. The sex of 1 patient was not reported.
b Indicates cholesterol level of more than 200 mg/dL, low-density lipoprotein level of at least 130 mg/dL, or high-density lipoprotein level of less than 30 mg/dL.
cCalculated as weight in kilograms divided by height in meters squared.
d Indicates eGFR of less than 30 mL/min/1.73 m2.
e Indicates hemoglobin level of less than 10 g/dL.
fCalculated as comparison of seropositivity for HIV test with negative/unknown results.
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Table 2. Sociodemographic and Risk Factor Profile of HF Patients According to Endemic vs Emerging Causes
Characteristica
All Patients
(N=1006)
Endemic Causes
(n=473)
Emerging Causes
(n=506)
Sex-Adjusted
Differenceb
Men
(n=197)
Women
(n=276)
Men
(n=287)
Women
(n=219)
Difference
(95% CI) P Value
Sociodemographic Profile
Age, y
Mean (SD) 52.3 (18.3) 46.8 (18.2) 41.0 (18.3) 59.0 (13.7) 62.6 (13.6) 17.0
(15.0 to 19.1) .001Median (IQR) 55.0 (39.0-67.0) 46.0 (34.0-59.0) 36.0 (25.0-54.0) 60.0 (50.0-69.0) 64.0 (55.0-73.0)
Risk factor profile, No./
No. not missing (%)
Total cholesterol level
193 mg/dL
112/649 (17.3) 16/129 (12.4) 21/190 (11.1) 44/185 (23.8) 30/128 (23.4) 11.9
(5.9 to 17.9)
.001
History of smoking 98/1001 (9.8) 34/197 (17.3) 6/276 (2.2) 50/285 (17.5) 7/218 (3.2) 0.9
(−1.8 to 3.6)
.50
Hypertension 555/1001
(55.4)
43/197 (21.8) 60/274 (21.9) 247/286 (86.4) 189/219 (86.3) 64.5
(59.6 to 69.3)
.001
Type 2 diabetes mellitus 114/1003
(11.4)
14/197 (7.1) 17/276 (6.2) 43/285 (15.1) 37/219 (16.9) 9.3
(5.3 to 13.3)
.001
BMI 30 158/969 (16.3) 14/188 (7.4) 41/269 (15.2) 43/278 (15.5) 52/210 (24.8) 8.6
(4.1 to 13.1)
.001
Clinical Presentation
NYHA, No./No. not missing (%)
II 303/706 (42.9) 60/141 (42.6) 97/200 (48.5) 72/200 (36.0) 67/147 (45.6)
III 216/706 (30.6) 46/141 (32.6) 49/200 (24.5) 69/200 (34.5) 47/147 (32.0)
IV 28/706 (4.0) 4/141 (2.8) 8/200 (4.0) 13/200 (6.5) 2/147 (1.4)
Systolic blood pressure, mm Hg
Mean (SD) 130.4 (33.5) 116.1 (28.5) 115.7 (24.3) 143.8 (32.3) 143.8 (36.4)
27.9
(24.0 to 31.8) .001Median (IQR) 127
(106 to 150)
110.0
(100.0 to 130.0)
110.0
(100.0 to 130.0)
140.0
(120.0 to 160.0)
140.0
(120.0 to 160.0)
Diastolic blood pressure,
mm Hg
Mean (SD) 84.3 (20.9) 76.5 (19.5) 77.1 (17.0) 92.0 (19.8) 90.9 (22.4)
14.6
(12.1 to 17.1) .001Median (IQR) 80
(70 to 100)
73.0
(65.0 to 89.0)
75.0
(67.0 to 90.0)
90.0
(80.0 to 100.0)
90.0
(79.0 to 100.0)
Heart rate, bpm
Mean (SD) 103.7 (21.6) 103.8 (24.3) 109.1 (22.4) 100.2 (19.3) 101.7 (20.0)
−5.5
(−8.3 to −2.8) .001Median (IQR) 104
(90 to 116)
102.0
(89.0 to 116.0)
111.0
(93.0 to 122.0)
100.0
(88.0 to 112.0)
103.0
(89.0 to 112.0)
Peripheral edema scorec
Mean (SD) 1.8 (1.0) 1.9 (1.0) 1.7 (1.0) 1.9 (1.1) 1.8 (1.1)
0.1
(−0.1 to 0.2) .35Median (IQR) 2.0
(1.0 to 3.0)
2.0
(1.0 to 3.0)
2.0
(1.0 to 3.0)
2.0
(1.0 to 3.0)
2.0
(1.0 to 3.0)
Echocardiographic Evaluation
Heart rate, bpm
Mean (SD) 94.6 (17.9) 97.3 (18.4) 98.1 (18.9) 91.1 (17.5) 9.19 (15.9)
−6.2
(−8.7 to −3.6) .001Median (IQR) 94.0
(84.0 to 104.0)
96.5
(87.5 to 105.0)
98.0
(88.0 to 110.0)
90.9
(80.0 to 102.0)
92.0
(81.0 to 101.0)
Dimensions and LV Function
LV systole size, mm
Mean (SD) 46.0 (13.1) 49.3 (13.4) 45.7 (13.5) 47.3 (12.6) 42.8 (12.3)
−2.4
(−4.1 to −0.8) .004Median (IQR) 47.0
(37.0 to 55.0)
51.0
(39.0 to 58.8)
46.7
(36.0 to 55.0)
48.0
(39.5 to 55.0)
43.4
(33.0 to 53.0)
LV diastole size, mm
Mean (SD) 57.7 (11.6) 60.9 (11.5) 57.9 (11.9) 58.6 (11.3) 54.0 (10.7)
−3.1
(−4.5 to −1.6) .001Median (IQR) 58.0
(50.0 to 65.0)
62.0
(54.0 to 68.0)
58.0
(50.0 to 65.0)
58.7
(53.0 to 65.0)
54.0
(46.0 to 63.0)
Ejection fraction, %
Mean (SD) 39.1 (16.3) 36.9 (16.4) 40.2 (17.1) 37.3 (15.4) 40.8 (15.5)
0.6
(−1.5 to 2.7) .59Median (IQR) 37.2
(26.0 to 50.0)
35.0
(24.0 to 49.0)
38.0
(27.0 to 53.0)
37.0
(25.0 to 47.0)
39.5
(29.4 to 50.0)
Intraventricular septum
(diastole), mm
Mean (SD) 11.2 (3.3) 10.7 (3.1) 9.8 (3.1) 12.3 (3.1) 11.8 (3.0)
1.8
(1.4 to 2.2) .001Median (IQR) 11.0
(9.0 to 13.0)
10.0
(9.0 to 12.1)
9.6
(8.0 to 11.0)
12.0
(10.0 to 14.0)
11.3
(10.0 to 13.4)
(continued)
ARCH INTERN MED/VOL 172 (NO. 18), OCT 8, 2012 WWW.ARCHINTERNMED.COM
1390
©2012 American Medical Association. All rights reserved.
Downloaded From: http://archinte.jamanetwork.com/ on 03/28/2014
differ by sex (Tables 1 and 2), probably contributing to
slight differences in outcomes (Table 3).
Three important observations are worth noting about
medical therapy for AHF (Figure 3). First, we have ob-
served ahigh incidence of theuse of aspirin inpatientswith
nonischemic HF in the sub-Saharan African region. In ad-
dition, the combination of hydralazine hydrochloride and
nitrates, which has been shown to be effective in patients
of African descent,19,20 is hardly ever used in the sub-
Saharan region. Third, the rate of -blocker use, even at
follow-up, is relatively low. Althoughmany patients in the
present study haveHFwith preserved systolic function for
which the use of -blockers is less clearly indicated, the
rate of-blocker use in THESUS–HF is lower than that de-
scribed in other regions.18,21,22 These observations provide
an opportunity to improve the quality of the care of pa-
tients with HF in the region. A larger randomized study
investigating the combination treatment with hydralazine
and nitrates vs placebo inAfricans admittedwithAHFwill
commence soon in the centers that participated in the
THESUS–HF registry.
The cause of AHF remains predominantly nonis-
chemic, with hypertension, rheumatic heart disease, and
the endemic cardiomyopathies (ie, idiopathic dilated car-
diomyopathy, peripartum cardiomyopathy, and endo-
myocardial fibrosis) accounting for 75.5% of the cases
(Figure 2 andTable 2). Although the rate of ischemic heart
disease may have been underestimated owing to limited
diagnostic tools, this finding is in striking contrast to reg-
istries in Europe or the United States,18,21,22 where ische-
mic heart disease (a rarity in Africa) accounts for most
of the cases. However, Africa is clearly facing an addi-
tional burden because, in addition to the high preva-
lence of endemic diseases, we are observing a high (and
probably increasing) burden of emerging diseases, such
as ischemic heart disease and hypertension, in particu-
lar in some countries (Figure 3). As socioeconomic
changes continue to progress across the continent, the
Table 2. Sociodemographic and Risk Factor Profile of HF Patients According to Endemic vs Emerging Causes (continued)
Characteristica
All Patients
(N=1006)
Endemic Causes
(n=473)
Emerging Causes
(n=506)
Sex-Adjusted
Differenceb
Men
(n=197)
Women
(n=276)
Men
(n=287)
Women
(n=219)
Difference
(95% CI) P Value
Dimensions and LV Function
Posterior wall (diastole), mm
Mean (SD) 10.7 (2.9) 10.2 (2.9) 9.5 (2.7) 11.7 (2.7) 11.2 (2.7)
1.6
(1.2 to 2.0) .001Median (IQR) 10.2
(9.0 to 12.9)
10.0
(8.0 to 12.0)
9.2
(8.0 to 11.0)
12.0
(9.9 to 13.6)
11.0
(9.4 to 13.0)
Diastolic Function
Left atrial anteroposterior
size, mm
Mean (SD) 47.1 (9.2) 49.1 (9.7) 47.4 (10.5) 46.9 (8.1) 45.7 (7.8)
−1.9
(−3.1 to −0.8) .001Median (IQR) 47.0
(41.0 to 53.0)
48.6
(43.0 to 55.0)
47.0
(41.0 to 53.0)
47.0
(42.0 to 52.0)
45.0
(40.0 to 50.9)
Left atrial planimetry size, mm2
Mean (SD) 2782 (924) 3039 (1001) 2882 (1110) 2782 (770) 2532 (7808)
−306
(−465 to −147) .001Median (IQR) 2635
(2200 to 3285)
2930
(2250 to 3540)
2770
(2130 to 3400)
2728
(2295 to 3200)
2478
(2100 to 2900)
Mitral E wave, cm/s
Mean (SD) 544.2 (500.6) 537.1 (587.0) 571.3 (585.6) 529.6 (404.7) 529.4 (449.7)
−25.8
(−97.0 to 45.4) .48Median (IQR) 480.0
(96.0 to 880.0)
243.0
(87.2 to 810.0)
332.0
(88.0 to 920.0)
526.0
(101.7 to 880.0)
460.0
(102.2 to 880.0)
E-wave deceleration time, ms
Mean (SD) 150.0 (92.1) 151.3 (146.2) 145.3 (102.9) 143.2 (54.6) 159.0 (64.4)
3.6
(−9.8 to 17.0) .60Median (IQR) 130.0
(100.0 to 171.0)
120.0
(92.0 to 158.0)
122.0
(100.0 to 165.0)
134.0
(106.0 to 171.0)
140.6
(120.0 to 189.0)
Mitral A wave, m/s
Mean (SD) 324.4 (330.2) 302.0 (289.3) 334.9 (396.1) 295.5 (274.9) 365.5 (344.9)
13.3
(−38.5 to 65.0) .61Median (IQR) 215.0
(53.0 to 513.0)
206.0
(52.6 to 500.0)
149.5
(44.2 to 498.0)
220.0
(59.6 to 498.0)
270.0
(69.0 to 580.0)
Mitral A-wave duration, ms
Mean (SD) 126.4 (45.1) 114.3 (38.1) 126.7 (57.5) 130.7 (44.1) 128.4 (34.2)
8.5
(0.6 to 16.4) .03Median (IQR) 123.0
(100.0 to 150.0)
20.0
(90.0 to 140.0)
118.0
(100.0 to 150.0)
130.0
(100.0 to 160.0)
128.0
(101.0 to 150.0)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HF, heart failure; IQR, interquartile range; LV, left
ventricular; NYHA, New York Heart Association class.
SI conversion factor: To convert cholesterol to millimoles per liter, multiply by 0.0259.
aStatistics are computed from nonmissing values, the number of which may vary from variable to variable. The HF causes were reported for 980 patients; sex was not
reported for one of these.
bCalculated as the sex-adjusted difference in proportions or means between endemic and emerging causes of HF.
cExamined in a dependent area, including the lower extremities and sacral area, and scored as 0 (a complete absence of skin indentation with mild digital pressure in
all dependent areas), 1 (indentation of the skin that resolves in 10-15 seconds), 2 (indentation of the skin that is easily created with limited pressure and disappears
slowly [15-30 seconds or longer]), or 3 (large areas of indentation are easily produced and slow [30 seconds] to resolve).
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number of AHF cases (particularly in women) caused by
noncommunicable forms of heart diseasemay further in-
crease. Finally, human immunodeficiency virus infec-
tion, which can affect themyocardium in various ways,23
is a common condition among patients withHF in Africa.
Whether the early introduction of antiretroviral therapy
in human immunodeficiency virus–seropositive pa-
tients with HF and otherwise no indication for antiret-
roviral therapy will change their outcome remains to be
established in future studies.
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Figure 3. Primary causes of heart failure by country. CMO indicates cardiomyopathy; HD, heart disease; and HIV, human immunodeficiency virus.
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Figure 4. Prescribed oral medication. ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; FU, follow-up.
Table 3. Clinical Outcomesa
Outcome
Patient Groups Causes of HF
All
(N=1006)
Men
(n=494)
Women
(n=511)
Endemic
(n=473)
Emerging
(n=506)
Length of initial hospital stay, d
Mean (SD) 9.2 (9.3) 9.4 (10.4) 9.1 (8.1) 9.8 (11.5) 8.7 (6.6)
Median (IQR) 7 (5-10) 7 (5-10) 8 (5-10) 8 (5-11) 7 (5-10)
Initial hospitalization mortality, No. (%) 42 (4.2) 24 (4.9) 18 (3.5) 28 (5.9) 14 (2.8)
Readmission to day 60 9.1 (7.3-11.3) 9.7 (7.2-13.1) 8.5 (6.2-11.6) 9.4 (6.8-12.8) 9.0 (6.6-12.2)
Death to day 60 10.6 (8.7-12.8) 11.0 (8.4-14.3) 10.2 (7.7-13.4) 12.5 (9.7-16.0) 9.0 (6.7-12.1)
Death or readmission to day 60 15.6 (13.3-18.1) 16.6 (13.5-20.5) 14.5 (11.6-18.2) 17.3 (14.0-21.2) 14.1 (11.2-17.8)
Death to day 180 17.8 (15.4-20.6) 18.3 (14.9-22.4) 17.4 (14.1-21.4) 20.5 (16.9-24.8) 15.5 (12.4-19.4)
Abbreviations: HF, heart failure; IQR, interquartile range.
aUnless otherwise indicated, data are expressed as Kaplan-Meier estimate (95% CI).
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Few studies of the outcome of HF in sub-Saharan
Africa exist.24 The outcome of AHF in this study, includ-
ing high in-hospital and 6-month mortality rates (the
latter a possible underestimation owing to higher rates
of loss to follow-up) are remarkably similar to those
observed in registries in Europe and the United
States.18,21,22 This finding is remarkable because this
almost identical outcome was registered despite large
differences in patient characteristics (eg, a 20-year differ-
ence in age) and causes of HF, suggesting that once AHF
occurs, it may have a distinct course independent of
patient characteristics. When we compared endemic and
emerging causes, AHF due to emerging causes had a
slightly better outcome, probably secondary to the better
outcome of hypertensive AHF. However, these data
should be confirmed in other studies.
Our study’s limitations deserve mention. Loss to fol-
low-up was higher in THESUS–HF than in studies con-
ducted in other regions. This finding is common in the
population studied owing to such factors as the opportu-
nity towork if the patient is still healthy (in the case ofmi-
grantworkers) or theneed toobtain care if unhealthy. Some
inhabitants of those regions have no telephone contact.
This registry has been compiled in selected centers and
may represent only AHF patients seen in specialized cen-
ters. This limitation has to be seen in the context that
manyAfrican countries do not train cardiologists and that
access to cardiac ultrasonography is limited.
Unfortunately, there are no criterion standards for de-
finitively categorizing HF. We applied a clinically ori-
ented approach based on published criteria. As a clini-
cal registry, we did not systematically validate diagnostic
criteria. Owing to no access to cardiac catheterization in
a number of centers, we might have missed HF due to
ischemic origin.
CONCLUSIONS
Acute HF affects patients in sub-Saharan Africa at an ex-
tremely early age and is caused mostly by hypertension
and primary cardiomyopathies. The disease leads to a high
burden of readmission and death, similar to that ob-
served in other countries, affecting younger patients in
the prime of their life. These data challenge us to recog-
nize and respond to HF in Africa by responding to com-
monprecursors, such as hypertension and the urgent need
for culturally sensitive interventions. Dedicated aware-
ness programs that strive to improve the pharmacologi-
cal and nonpharmacological management of AHF (in-
cluding better follow-up) need to be developed.
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